Watch Ticker

Cerevel Therapeutics Holdings, Inc. Common Stock

Go to Cerevel Therapeutics Holdings, Inc. Common Stock Website

$44.96

(%)

Live

Previous Close

$44.96

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

Day Vol.

Previous Day Vol.

Currency

Primary Exchange

Nasdaq

...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Zacks Equity Research - Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?

AbbVie reported strong Q2 results, beating estimates for earnings and sales. The company's ex-Humira drugs, such as Rinvoq and Skyrizi, performed well, offsetting the decline in Humira sales. AbbVie raised its 2024 guidance for earnings and sales, driven by the strong performance of its newer drugs.

Related tickers: ABBV, CERE, GMAB.

Read Full Article

Zacks Equity Research - AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock? - Zacks Investment Research

AbbVie has successfully navigated the loss of exclusivity for its blockbuster drug Humira by launching new immunology medicines, Skyrizi and Rinvoq, which are expected to drive future growth. The company also has an attractive pipeline and has made accretive acquisitions to strengthen its portfolio.

Related tickers: ABBV, AMGN, GMAB, CERE.

Read Full Article

Trending Tickers

Please sign in to view